A clinical trial using a novel Australian-made treatment for pancreatic cancer is recruiting eligible patients in Queensland.
Australian biotech company Amplia Therapeutics has extended its ACCENT trial, which has been operating since August 2022 in Melbourne and Sydney, to Queensland.